Neurocrine Biosciences Inc. filings document the regulatory record of a commercial biopharmaceutical company developing and selling treatments for neurological, psychiatric, endocrine and immunological disorders. Its 8-K reports cover operating and financial results, product-sales disclosures, clinical or regulatory updates, material agreements, capital-structure matters and executive or employment-related governance events.
Proxy filings describe board matters, shareholder voting items, executive compensation, equity awards and pay-versus-performance disclosures. The filing record also includes formal disclosures related to INGREZZA, CRENESSITY and the company's pipeline, as well as risk, governance and transaction-related disclosure categories relevant to its public-company status.
Neurocrine Biosciences, Inc. common stock was the subject of JPMorgan Chase & Co.'s report of beneficial ownership of 5,300,390 shares, representing 5.2% of the class as of September 30, 2026. JPMorgan reported sole voting power over 4,725,485 shares and shared voting power over 22,400 shares; it reported sole dispositive power over 5,294,407 shares and shared dispositive power over 665 shares.
Neurocrine Biosciences (NBIX) Chief Medical Officer Eiry Roberts reported 51,331 shares of common stock as of September 28, 2026. Of those, 50,146 shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, over which Dr. Roberts has voting and investment power. The report also lists options over common shares, including 60,005 shares at a $79.02 exercise price, expiring January 31, 2032, and 2,114 restricted stock units scheduled to vest February 13, 2027, subject to award terms.
Neurocrine Biosciences (NBIX) appointed Eiry W. Roberts, M.D., as chief medical officer effective September 28, 2026, succeeding Sanjay Keswani, M.D., whose service ended September 25, 2026 by mutual agreement. Keswani is entitled to severance benefits under the company’s Executive Severance Plan, subject to its terms.
The company said it will enter into an amended and restated employment agreement with Roberts, effective September 28, 2026. Under its described terms, she would receive an annual base salary of $825,000 and a 2026 annual cash incentive bonus target equal to 60% of base pay earned. Target equity grant values are approximately $625,000 in stock options, $250,000 in restricted stock units and $375,000 in performance-vesting restricted stock units. Options vest in equal monthly installments over four years, and restricted stock units in equal annual installments over four years; performance units follow the terms for executive officers’ February 2026 grants. The equity grants will automatically be made two business days after the company files its first Form 10-Q following the transition, provided Roberts remains employed on that date.
NEUROCRINE BIOSCIENCES INC (NBIX) reported that Chief Scientific Officer Jude Onyia acquired 3,587 shares of Common Stock on September 11, 2026 from the vesting of previously granted performance restricted stock units (PRSUs) after a performance metric was certified as achieved.
On the same date, 1,936 shares were withheld by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements related to that vesting at a reference price of $156.22 per share; the company states that no shares were sold, and no Rule 10b5-1 trading plan is reported.
NEUROCRINE BIOSCIENCES INC (NBIX) reported that Chief Legal Officer Darin Lippoldt received 4,483 shares of common stock on September 11, 2026 through the vesting of previously granted performance restricted stock units (PRSUs) after achievement of a specified performance metric was certified.
On the same date, 2,419 shares were withheld by the company at $156.22 per share to satisfy tax withholding requirements related to the PRSU vesting, and the disclosure states that no shares were sold. No Rule 10b5-1 trading plan is reported.
NEUROCRINE BIOSCIENCES INC (NBIX) reported that Chief Medical Officer Sanjay Chandru Keswani had performance restricted stock units vest upon achievement of a certified performance metric on September 11, 2026, resulting in an acquisition of 3,914 shares of common stock. On the same date, 2,112 shares were withheld by the company at $156.22 per share to satisfy tax withholding requirements on the vesting; the company states that no shares were sold in the market.
NEUROCRINE BIOSCIENCES INC (NBIX) director Kevin Charles Gorman reported equity compensation activity on September 11, 2026. He acquired 14,343 shares of common stock at no cost upon vesting of previously granted performance restricted stock units after a performance metric was certified as achieved.
On the same date, 7,839 shares of common stock were withheld by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements related to the PRSU vesting at a reference price of $156.22 per share; no shares were sold into the market. Following these transactions, 517,797 outstanding shares are held by the Gorman and Blais Family Trust, over which Dr. Gorman has voting and investment power.
NEUROCRINE BIOSCIENCES INC (NBIX) reported that Chief Executive Officer and director Kyle Gano had performance-based equity awards vest on September 11, 2026, resulting in acquisitions of 6,275 and 1,842 shares of common stock at no cost upon certification of a performance metric. On the same date, 3,386 and 994 shares were withheld by the company at $156.22 per share to satisfy tax withholding obligations on the vesting of these PRSUs; the filing states that no shares were sold and no Rule 10b5-1 trading plan is reported.
NEUROCRINE BIOSCIENCES INC (NBIX) reported that Chief Regulatory Officer Ingrid Delaet received a grant of 4,483 shares of common stock on September 11, 2026 upon certification of a performance metric tied to previously awarded performance restricted stock units (PRSUs). On the same date, 2,419 shares were withheld by the company at a price of $156.22 per share to satisfy tax withholding requirements on the PRSU vesting, and the filing specifies that no shares were sold. No Rule 10b5-1 trading plan was reported for these transactions.
NEUROCRINE BIOSCIENCES INC (NBIX) reported that Chief Human Resources Officer Julie Cooke received a grant/award of 3,587 shares of Common Stock on September 11, 2026 upon certification of a performance metric for previously granted performance restricted stock units (PRSUs). On the same date, 1,936 shares were withheld by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements on the PRSU vesting at a value of $156.22 per share; no shares were sold in the market. The filing notes that 21,985 of the reported shares are held by the Cooke Family Trust of 2004, over which Julie Cooke has voting and investment power, and no Rule 10b5-1 trading plan is reported.